Podcasts about transplantation

Gastrointestinal complications are common—but often underrecognized—after lung transplantation. From diarrhea and nausea to malabsorption and poor appetite, these challenges can seriously impact recovery and long-term health outcomes.In this episode of the DNS Podcast, host Christina Rollins speaks with Bridget Doyle, MS, RD, LDN, CNSC, a transplant dietitian specializing in lung transplant nutrition. Bridget shares her expertise on identifying, managing, and supporting patients through complex GI issues post-transplant.Listeners will gain insights on:✅ The most frequent GI complications following lung transplant✅ How medications like immunosuppressants and antibiotics affect digestion✅ Practical nutrition strategies for diarrhea, nausea, and poor intake✅ Food safety guidance for immunocompromised patients✅ When to consider enteral or parenteral nutrition support✅ Key labs and nutrients to monitor for optimal recoveryTune in to hear evidence-based strategies for improving GI health and supporting successful long-term outcomes for transplant recipients. Visit us at dnsdpg.org to learn more.

This bonus content is a reading from Platypus, the CASTAC Blog. The full post by Juliana Vieira can be read at https://blog.castac.org/2025/10/uterus-transplantation-a-scientific-advance-or-the-reflection-of-gender-stereotypes/. About the post: After all, to what extent do highly innovative medical technologies, such as uterus transplantation, cease to express a progressive vision of the future and instead reinforce morally conservative values related to motherhood, gender, and gestation? (This episode is available in additional languages on Platypus, The CASTAC Blog.)

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

Cool air and warm soils mean that it's a great time to divide and multiply the plants that you love, and Leslie and Marianne want to help you do it easily, efficiently, and with the least amount of plant pain as possible. What are they dividing in their gardens and how are they doing it? And why is it so good for the plants to rip them from happy homes just when they were thinking of taking a well-earned nap? For that matter, why aren't the girls sipping pumpkin lattes and waiting ‘till spring? Set down that bulb planter and grab those two forks, because it's all about FREE this week on The Garden Mixer. (Just for the record Marianne hates pumpkin lattes. Leslie's a fan.)___________________Be sure to hit the subscribe button so we can keep you smiling while you hit the mess [your garden] out there.Full Show Notes at⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠The Garden Mixer Podcast's Substack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠____________________Socials – Pick Your Platform:Follow us on Instagram⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@thegardenmixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indulge us on TikTok⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@the.garden.mixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spar with us on X⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@gardenmixerpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠“French Bistro” theme by Adieu Adieu. License D0LZBINY30GGTBBW

Première européenne: transplantation cardiaque partielle réussie chez un enfant Les brèves du jour Le bric à brac de Sapiens 5/5: un artiste nommé Sapiens "Vaccinez-moi" (2025) d'Alex Fredo pour parler des vaccins

It seems like every week, there's a new headline about some kind of sci-fi-esque organ transplant. Think eyeballs, 3D-printed kidneys, pig hearts.In her new book, Replaceable You: Adventures in Human Anatomy, science writer Mary Roach chronicles the effort to fabricate human body parts—and where that effort sometimes breaks down. Host Flora Lichtman speaks with Roach about everything from hair transplants to 3D-printed hearts, and why our anatomy is so hard to replicate in the first place.Guest: Mary Roach is a science writer and the author of Replaceable You: Adventures in Human Anatomy.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dans cet épisode, on lève le voile sur un sujet méconnu mais essentiel : le don de tissus humains. Caroline, coordonnatrice en prélèvement et développement, et Jimmy, spécialiste en tissus humains, nous expliquent comment ces dons peuvent transformer des vies, et pourquoi il est crucial d'en parler. Un échange éducatif, humain et sans filtre.  Nous vous rappelons que, si vous consentez au don de tissus, vous pouvez dès maintenant signer votre carte d'assurance maladie (RAMQ). L'autocollant à apposer sur la carte peut être commandé en ligne sur https://publications.msss.gouv.qc.ca/msss/document-000065/ ou encore, il vous sera remis lors du renouvellement de votre carte. Il est également essentiel d'en discuter avec vos proches afin de clarifier les volontés et décisions de chacun.  Le jeu de Carte Héma-Québec "La question qui tue pas" sera disponible, jusqu'à épuisement des stock, dans les Centres de dons Héma-Québec. 

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Send us a textDr. Michael McCullar, PhD is Chief Executive Officer  of RegCell ( https://regcellbio.com/ ), a biotechnology company has developed a best-in-class proprietary platform that allows the generation of epigenetically reprogrammed antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-Epigen-Tregs) to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation.Dr. McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades. Throughout his career, he has been involved in various aspects of drug development and played pivotal roles in the success of several pharmaceutical companies. Dr. McCullar formerly served as the CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities. Before that, he was Chief Operating Officer at Tolero Pharmaceuticals, where he had a prominent role in the company's acquisition by Sumitomo Dainippon Pharma and also served as the Senior Vice President of Business Development at Astex Pharmaceuticals, during it's acquisition by Otsuka Pharmaceuticals. Dr. McCullar has held several high-level executive positions at SuperGen, showcasing his commitment and upward career path within the company. His journey at SuperGen culminated in the role of Senior Vice President of Strategy and Operations, where his expertise paved the way for the U.S. Food and Drug Administration (FDA) approval of Dacogen as a treatment for myelodysplastic syndromes, and the acquisition of Astex Therapeutics, which resulted in the formation of Astex Pharmaceuticals, Inc.Dr. McCullar holds a Ph.D. in Toxicology from the University of California, Riverside and an MBA from the W.P. Carey School of Business at Arizona State University.#MichaelMcCullar #RegCell #RegulatoryTCells #Tregs #AutoimmuneDisorders #Transplantation #ShimonSakaguchi #ImmuneSystem #SelfAntigens #Tolerance #AntiInflammatoryCytokines #AntigenPresentingCells #Thymus #BoneMarrow #Anergy #AntigenSpecificTregs #AntigenTargeting #Homing #EpigeneticEditing #Reprogramming #AutologousManufacturing #Japan #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses. Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 

Return to Sport After Meniscal Allograft Transplantation in Collegiate and Professional Athletes Sachs JP, Mufti YN, Rubin J, et al. Am J Sports Med. 2025 Sep 3. doi:10.1177/03635465251366445 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

In a special co-branded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosing interleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses.  Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk. As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.

Allein in Deutschland warten derzeit 5000 Patientinnen und Patienten auf eine Transplantation der Hornhaut; weltweit sind es sogar rund 13 Millionen Menschen. Eine künstliche Hornhaut, wie sie Oberarzt Dr. Joel Lüthy an der Asklepios Klinik Nord Heidberg im vergangenen November erstmals in Norddeutschland eingesetzt hat, könnte vielen Betroffenen schneller helfen. Wie der Eingriff funktioniert und für wen er infrage kommt, erklärt der Augenarzt in dieser Podcast-Folge.

Tamara Schwab hat mit Ende 20 ein neues Herz erhalten. Rund vier Jahre später ist sie Autorin, Trainerin für die Themen Resilienz, Change und Erfolg und außerdem Botschafterin der Deutschen Herzstiftung. Im Gespräch erzählt sie von den sichtbaren und unsichtbare Narben, die eine solche Herzverpflanzung hinterlässt – und wie man trotzdem den Lebensmut behält. Triggerwarnung: Es geht in dieser Episode um sensible Inhalte wie Tod und Transplantation.

Spenderorgane sind rar und begehrt. Daher werden auch Tiere zu Organspendern. Noch ist die Xenotransplantation im Versuchsstadium. Doch das Forschungsfeld macht enorme Fortschritte. (00:32) Tierorgane werden immer menschlicher und die Überlebenschancen von Transplantierten immer grösser. Gentechnik macht es möglich, dass die Verpflanzung von tierischen Organen allmählich zu einer realistischen Alternative wird. Bereits schon ein halbes Jahr lebt ein Mensch, der eine Schweineniere erhalten hat. Vor kurzem wurde erstmals eine Schweinelunge in einen Menschen verpflanzt. Eine besonders komplizierte Transplantation. Jetzt versammeln sich Wissenschaftler:innen in Genf zur internationalen Xenotransplantations-Konferenz IXA (Irène Dietschi) (06:42) Meldungen: - Neue Neurblastom-Therapie aus Zürich - Erste Gentherapei gegen Chorea Huntington - Gigantische Felsenkunst in der Arabischen Wüste (Katharina Bochsler (15:37) Zwei Vulkane haben ein unterirdisches Verhältnis Anfang 2025 hat es auf Santorini tüchtig gerumpelt. Eine Reihe von Erdbeben bewegte die Inselgruppe in der südlichen Ägäis. Der Vulkan unterhalb des Kykladen-Archipels war spürbar unruhig geworden. Und nicht nur er, wie sich jetzt zeigt. Mitgewirkt hat auch der sieben Kilometer entfernte submarine Vulkan Kolumbos. Denn Forschende haben jetzt entdeckt: die beiden Vulkane teilen sich eine gemeinsame Magmakammer (Anita Vonmont) (21:16) Das Konzept der wasserreichen Exoplaneten verdampft Eine ETH-Studie widerlegt die Hypothese, wonach weit draussen im Kosmos von riesigen Ozeanen bedeckte - sogenannt hyzänische - Planeten kreisen. Dieses Konzept bewohnbarer Exoplaneten schürte in den letzten Jahren die Hoffnung, Leben im All zu finden. Forschende der ETH Zürich kommen nun zum Schluss: Diese «Wasserwelten» sind wohl nur Fiktion. In der Realität würde ein Grossteil des Wassers bald nach der Geburt der Planeten durch chemische Prozesse verschwinden. (Sandro Della Torre) LINKS Xenotransplantation IXA Konferenz: ixa2025.org Neuroblastom: nature.com/articles/s41586-025-09564-0 Gentherapie Chorea Huntington: uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii Planetary health Check: planetaryhealthcheck.org Kosmische Wasserwelten: iopscience.iop.org/article/10.3847/2041-8213/adff73

AJT October 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Christina Haugen to discuss the key articles of the October issue of the American Journal of Transplantation. Dr. Christina Haugen is an Assistant Professor of Surgery at the University of Cincinnati. [03:28] Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes—An analysis of COMPARE trial data [10:26] Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation [19:21] Potential targeting of urokinase-type plasminogen activator receptor–formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies [30:20] The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures [36:03] Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Hosts Roz and Dr. Sanchez-Fueyo discuss the key articles of the September issue of the American Journal of Transplantation. [03:30] Blunted cardiac reserve as a marker of cirrhotic cardiomyopathy—Cardiac outcomes following liver transplantation and comparison to the existing guidelines [14:18] Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial [25:55] Donor-derived cell-free DNA is associated with the degree of immunosuppression in lung transplantation [36:24] A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation [45:00] Cell therapy with human Interleukin 10–producing ILC2s enhances islet function and inhibits allograft rejection

In this episode, we are joined by Dr. Emile Bacha to discuss the emerging field of partial heart transplantation. The conversation explores the history of the concept, its reintroduction in recent years, and how techniques such as domino procedures are being developed to expand donor availability. Dr. Bacha explains the practical challenges of regulation, organ procurement, and immunosuppression, as well as early outcomes seen in paediatric patients. With reflections on valve durability, patient growth, and the future potential of this approach, this episode offers a detailed look into a promising area of congenital cardiac surgery and beyond.

Vidcast:   https://www.instagram.com/p/DNd6KltPeD_/Transplantation immuno-geneticists at Sweden's Uppsala University Hospital have successfully used gene editing to modify human pancreatic islet cells such that these transplants are more histocompatible, survive longer, and function better.  Their single patient case report appeared in a recent issues of the New England Journal of Medicine.The recipient is a 42-year-old male juvenile-onset insulin-dependent diabetic. The researchers utilized CRISPR-Cas12b gene editing technology to delete genes that code for incompatible cell surface antigens while adding genes coding for protective antigens thereby making the donor pancreatic cells invisible to the recipient's immune system.Over a 12-week period, the limited number of gene-edited islet cells available for transplantation were able to reduce but not totally eliminate the recipients insulin requirement.  This proved the viability and functional integrity of the transplanted islet cells suggesting that transplantation of a larger complement of islet cells could provide a recipient's total insulin requirement therapy curing diabetes without the need for ongoing immunosuppression with its often toxic side effects.https://medicalxpress.com/news/2025-08-gene-islet-transplant-human-functional.htmlhttps://www.nejm.org/doi/10.1056/NEJMoa2503822#diabetes #insulin #isletcells #transplantation #geneediting #immunosuppression

Sonja Koppitz www.deutschlandfunkkultur.de, Plus Eins

In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002

Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna.   [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry

Dr. Chris Wiebe shares his expertise in use of HLA eplet mismatch load in estimating immunologic risk in transplantation. We cover considerations of de novo HLA-DSA formation, donor selection, impacts on post-transplant monitoring protocols, as well as immunosuppression.

What if we could reset our cellular batteries? In this fascinating deep dive into cutting-edge longevity science, Tom Benson from Mitrix Bio reveals how mitochondrial transplantation could revolutionize how we treat age-related diseases and potentially add decades of healthy living to our lives.The conversation begins by exploring the extraordinary nature of mitochondria – those tiny power plants within our cells that generate 95% of our body's energy through molecular rotors functioning like miniature jet turbines. With approximately a quadrillion mitochondria comprising 10% of our body weight, these ancient organelles trace back to a symbiotic merger with our cellular ancestors over a billion years ago.Unlike the nuclear DNA we inherit from both parents, our mitochondrial DNA comes almost exclusively from our mothers, creating fascinating maternal lineage patterns where thousands of family members share identical mitochondrial DNA. As we age, this mitochondrial DNA gradually accumulates damage, with factors like stress, smoking, and medical treatments accelerating deterioration. By our 90s, this decline reaches a critical threshold that appears to drive much of the aging process.The most exciting revelation comes in learning that mitochondria naturally move between cells in our bodies – and scientists are now leveraging this phenomenon through transplantation techniques. By harvesting mitochondria from stem cells grown in bioreactors and reinjecting them, researchers are seeing remarkable improvements in cognition, strength, and immune function in aged mice, essentially restoring youthful cellular energy levels. Human trials are already underway, though still at small scale.For anyone fascinated by the frontiers of longevity science and the quest to not just add years to life, but life to those years, this conversation offers a glimpse into one of the most promising approaches emerging today. https://mitrix.bio/Lies I Taught In Medical School : Free sample chapter- https://www.robertlufkinmd.com/lies/Complete Metabolic Heart Scan (20% off 'LUFKIN20') https://www.innerscopic.com/Fasting Mimicking Diet (20% off) https://prolonlife.com/Lufkin At home blood testing (20% off) https://siphoxhealth.com/lufkinMimio Health (15% off 'LUFKIN') https://mimiohealth.sjv.io/c/5810114/2745519/30611 Web: https://robertlufkinmd.com/X: https://x.com/robertlufkinmdYoutube: https://www.youtube.com/robertLufkinmdInstagram: https://www.instagram.com/robertlufkinmd/LinkedIn: https://www.linkedin.com/in/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinThreads: https://www.threads.net/@robertlufkinmdFacebook: ...

Your Health First: Advancements in Robotic Surgery & Live Liver Donation at Houston MethodistJoin Dr. Joe Galati on this episode of "Your Health First" as he speaks with leading surgeons from Houston Methodist Hospital, Dr. Simon and Dr. Yee Lee Cheah. Broadcasting live from 740 KTRH in Houston and worldwide on the iHeartRadio app every Sunday at 7:00 PM Central, this insightful discussion delves into the groundbreaking work being done in robotic surgery and the current status of the live donor liver transplant program at Houston Methodist.Dr. Simon and Dr. Cheah share their expertise on the numerous benefits of robotic surgery, highlighting the significant advantages for patients and the remarkable advancements in technology over the past 5-10 years. They also provide a comprehensive overview of the meticulous patient selection process for live liver donors and detail the structured program at Houston Methodist Hospital.Don't miss this opportunity to learn about the cutting-edge surgical techniques and life-saving transplant procedures making a difference in patient care.For more information:Dr. Simon & Dr. Cheah: www.houstonmethodist.orgDr. Joe Galati: www.drjoegalati.comGuest Biographies:Dr. Simon:Dr. Simon is a highly accomplished surgeon with a specialization in abdominal transplantation and hepatobiliary surgery. She earned her medical degree with honors from University College Cork Faculty of Medicine in Ireland in 2002 and completed her general surgery residency at Brown University Program, Rhode Island Hospital. Dr. Simon further honed her expertise with a research fellowship in Diagnostic Imaging at Brown University and an ASTS-certified fellowship in Abdominal Transplantation and Hepatobiliary Surgery at Lahey Hospital & Medical Center. Her clinical interests are extensive, encompassing both benign and malignant tumors of the liver, bile duct, and pancreas, including hepatocellular carcinoma and Klatskin tumors. She is also deeply involved in kidney transplantation, living and deceased donor liver transplantation, pancreatic carcinoma, robotic surgery, and surgery for portal hypertension. Dr. Simon is board-certified in general surgery by the American Board of Surgery and is a Fellow of the American College of Surgeons (FACS).Dr. Yee Lee Cheah:Dr. Yee Lee Cheah is a distinguished surgeon who joined the J.C. Walter Jr. Transplant Center at Houston Methodist Hospital in 2022. She graduated with honors from the Royal College of Surgeons in Ireland in 2000 and completed her General Surgery Residency at the Brown University Program. Dr. Cheah further specialized with an ASTS-accredited fellowship in Transplantation & Hepatobiliary Surgery at the Lahey Clinic. Prior to Houston Methodist, she played a pivotal role at the Asian American Liver Centre at Gleneagles Hospital, the largest adult living donor liver transplantation (LDLT) center in Southeast Asia, before returning to LHMC to develop their LDLT and robotic surgery programs. Her expertise lies in living donor liver transplantation, robotic transplantation, HPB surgery for benign and malignant disorders, and nutrition therapy for surgical patients. Dr. Cheah's main research interests are centered on living donor safety and robotic surgery. She has held faculty positions at Brown University and Tufts University and served as an Adjunct Assistant Professor at the National University of Singapore. Hosted on Acast. See acast.com/privacy for more information.

Alles Gute (nachträglich) zum Geburtstag, Heiko "Snäcki" Postel. Er will sich im Sommer Haare einpflanzen lassen. Die Freeses schenken ihm ein paar davon, beziehungsweise das Geld dafür. Jederzeit und so oft ihr wollt: Die NDR 2 Kult-Comedy direkt aus dem Mehrgenerationen-Haushalt der Familie Freese. Die Lasziv-zupackende Oma Rosi, Helikopter-Mama Bianca, Sohn Svenni und Untermieter und Labertasche Heiko: Die besten Folgen bekommt ihr jeden Morgen in der ARD Audiothek.

Hosts Roz and Alberto discuss the key articles of the July issue of the American Journal of Transplantation. [03:48] Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: an intention-to-treat analysis of long-term outcomes [13:42] 10 degree C static storage of porcine donation after circulatory death livers improves biliary viability and mitigates ischemia-reperfusion injury [22:20] Fewer medullary pyramids in the living kidney donor are associated with graft failure in the recipient [33:35] Microvascular inflammation in kidney allografts: New directions for patient management MOMOT (Mouse Models in Transplant) articles: Can mouse kidney transplant models inform mechanisms of injury and acceptance in clinical kidney transplantation? Best practices in islet transplantation in mice

This week we speak with congenital heart surgeon T. Konrad Rajab of Arkansas Children's Hospital about a recent report he co-authored on piglet experiments on partial heart transplantation. How did transplanted heart valves grow in comparison to standard homografts and how did the valvular function differ with time? Is there a minimum dose of immunosuppresion that can protect these valves and can this dose be lower than full heart transplantation immunosuppresion therapy? Is partial heart transplantation considered a potential life-long approach to valve replacement or mostly something used to allow for growth of valves during childhood? What do we know about the world's limited experience in humans of this approach? Dr. Rajab shares the answers this week in an exciting 'sci-fi' episode. The future is now.https://doi.org/10.1016/j.jacbts.2024.10.015

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Un bébé né après une transplantation utérine Les brèves du jour Quand la mode mettait notre santé en péril One Health: lutte contre les moustiques résistants et enjeux climatiques "Papa Tango Charlie" (1976) de Mort Shuman et Philippe Adler pour parler du triangle des Bermudes

Commentary by Satish Raj.

An expert panel highlights key presentations in multiplemyeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.CancerNetwork®, in collaboration with The American Societyfor Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP; Taha Al-Juhaishi, MD; and Muhammad Salman Faisal, MD. This expert panel convened to discuss key presentations and abstracts of interest at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featuring noteworthy developments in modalities like CAR T-cell therapy and transplantation across multiple myeloma, lymphoma, and other disease types.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington. Al-Juhaishi is the associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy Program at Oklahoma University Health Stephenson Cancer Center and an assistant professor of medicine at the University of Oklahoma College of Medicine. Faisal is a hematologist/oncologist at Oklahoma University HealthStephenson Cancer Center and serves as an ambassador for ASCO.The group highlighted several late-breaking abstracts,plenary sessions, and poster presentations focused on significant clinical trial data and other findings across the hematologic oncology landscape. Topics of interest included the following:Phase 1b/2 CARTITUDE-1 trial (NCT03548207,NCT05201781)1Long-term follow-up showed that approximately one-third(33%; n = 32) of patients with relapsed/refractory multiple myeloma maintained progression-free status for at least 5 years following a single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti). An equal likelihood of progression-free survival occurred in patients with high-risk cytogenetics or extramedullary plasmacytomas.With a median follow-up of 61.3 months, the median overall survival (OS) with cilta-cel was 60.7 months (95% CI, 41.9-notevaluable [NE]). Real-world axicabtagene ciloleucel (axi-cel; Yescarta) use2Across inpatient and outpatient treatment settings, safety and efficacy outcomes were comparable for patients who received axi-cel for relapsed/refractory large B-cell lymphoma.Multivariate analysis showed no associations between intended care setting and cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.Investigators noted that these real-world data support the consideration of axi-cel in appropriate outpatient settings.Phase 1b/2 NEXICART-2 trial (NCT06097832)3Investigators assessed NXC-201, a sterically optimized CAR T construct, as a treatment for patients with relapsed/refractory light chain amyloidosis, a population with no FDA-approved options.Among 12 patients who received the agent at 450x 106 cells, 100% achieved rapid and deep hematologic responses at a median time to first and best response of 7 and 26 days, respectively. With a median follow-up of 121 days (range, 29-289), no hematologic relapses or progression had occurred.References1.     Voorhees P, Martin T, Lin Y, et al. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2025;43(suppl 16):7507. doi: 10.1200/JCO.2025.43.16_suppl.75072.     Furqan F, Hemmer M, Tees M, et al. Trends and outcomes by inpatient and outpatient infusion of axicabtagene ciloleucel (axi-cel) in the US for patients (pts) with relapsed/refractory large B-celllymphoma (R/R LBCL). J Clin Oncol. 2025;43(suppl 16):7023. doi:10.1200/JCO.2025.43.16_suppl.70233.     Landau H, Hughes C, Rosenberg A, et al. Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201. J Clin Oncol. 2025;43(suppl 16):7508.doi:10.1200/JCO.2025.43.16_suppl.7508

Host Roz is joined by new co-host Alberto Sanchez-Fueyo, MD, PhD to discuss the key articles of the June issue of the American Journal of Transplantation. Dr. Sanchez-Fueyo is a Professor of Hepatology, and the Academic Director of the Institute of Liver Studies, King's College, London. [02:51] Recipient toll-like receptor 4 determines the outcome of ischemia-reperfusion injury in steatotic liver transplantation in mice [10:47] Association between everolimus combination therapy and cancer risk after liver transplantation: A nationwide population-based quasi-cohort study [21:35] Balancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch Editorial: Equitable allocation through human leukocyte antigen eplet matching: A promising strategy with several challenges [32:51] Impact of the lung allocation system score modification by blood type on US lung transplant candidates Editorial: From flawed to fairer: Reducing blood type bias in lung transplant allocation Recommended article: The economic value of a transplant nephrologist: The case for improving compensation models

In this specialty podcast, Dr. Alissar El Chediak is joined by Dr. Jon Odorico and Dr. Ron Parsons to discuss the current state of pancreas transplantation, identify barriers and strategies for referral and candidate selection, and discuss solutions to address the decline in procedures. Alissar El Chediak, MD is a transplant nephrologist at UT Southwestern Medical Center. Jon Odorico, MD is a transplant surgeon at the University of Wisconsin. Ron Parsons, MD is a transplant surgeon at the University of Pennsylvania.   References: Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report

Should animals ever be used as spare parts for humans? PETA Sr. VP Kathy Guillermo was interviewed by CNN about xenotransplantation.  Listen to what she had to say about the experience and the hope that her views are represented fairly.  See PETA represent the ethical perspective on xenotransplantation in the CNN documentary "Animal Pharm," which premieres Sunday, May 17. Find out more about xenotransplantation, go to PETA.org The PETA Podcast PETA, the world's largest animal rights organization, is 9 million strong and growing. Hosted by Emil Guillermo.  Contact us at PETA.org Music provided by CarbonWorks. Go to Apple podcasts and subscribe. Contact and follow host Emil Guillermo and get the podcast on YouTube. www.YouTube.com/@emilamok1 Please subscribe, rate, and review wherever you get your podcasts. Thanks for listening to THE PETA PODCAST! Originally released May 14, 2025,  ©PETA, Emil Guillermo 2023-25  

In this extraordinary episode, Prue shares her remarkable 11-year journey to motherhood, culminating in becoming the third woman in Australia to give birth following a uterus transplant. Her story is one of incredible perseverance, medical innovation, and the profound desire to become a mother against seemingly impossible odds. If you've been considering joining over 6000 families who have prepared for birth with confidence through The Birth Class now's your chance. You can enjoy 20% off in our Mother’s Day Sale with the code: MUM25Inside The Birth Class you’ll enjoy: 10 comprehensive audio lessons 5 guided meditations for pregnancy and birth 70-page detailed workbook Birth partner cheat sheet Birth positions poster Hospital bag checklist Birth preferences template Lifetime access Save 20% Now [ Code: MUM25 ] Sale ends 15th of May at midnight and applies to all our courses!See omnystudio.com/listener for privacy information.

Dr. Justin Abbatemarco provides an update on autologous hematopoietic stem cell transplantation in multiple sclerosis. Show reference: https://www.nature.com/articles/s41582-024-01050-x

Host: Darryl S. Chutka, M.D. Guest: John Haney, M.D., M.P.H. Lung transplantation remains a very viable option for patients with end-stage pulmonary disease who no longer respond to medical management. Over 5,000 lung transplants are performed annually around the world. However, its estimated that over 10 times this number are candidates and awaiting a transplant. A shortage of organs remains the major limiting factor. What are the common indications and who's a candidate for a lung transplant? How are patients prioritized and chosen? What advances have been made in the field and what challenges remain? Finally, what role does the primary care clinician play in lung transplantation? I'll be discussing these questions and more with my guest, Jack Haney, M.D., M.P.H., chair of cardiothoracic surgery at the Jacksonville campus of the Mayo Clinic. The topic for this podcast is “Lung Transplantation”. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Host: Darryl S. Chutka, M.D. Guest: Rohan M. Goswami, M.D. The benefits of artificial intelligence or AI are just beginning to be recognized. AI has the potential to improve productivity and efficiency in the workplace, reduce errors and help sort out complex issues. The field of healthcare is finding roles for AI by improving the management of patient data, enhancing clinical decision making and assisting in medical imaging analysis. The integration of AI in transplantation medicine is evolving and has the potential to revolutionize the field. Can AI assist in organ matching and allocation? Can it predict graft survival and organ rejection?  What ethical concerns does AI bring to the specialty?  I'll be discussing these issues in this podcast as we tackle the topic of “AI in Transplantation Medicine”. My guest for this podcast is Rohan M. Goswami, M.D., a cardiologist and specialist in Transplant Medicine from the Mayo Clinic. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development